PDF
ePub
Citation
Print
Abstract
Background
Vardenafil is a phosphodiesterase type 5 inhibitor, used in erectile dysfunction. This study aimed to evaluate the pharmacokinetics and tolerability of vardenafil following a single oral administration in healthy male subjects.
Methods
A randomized, double-blind, placebo-controlled, single dosing, dose-escalation study was conducted in 30 healthy subjects. A single oral dose of vardenafil or placebo was given to 10 subjects (8 active + 2 placebo) in each dose group of 5, 10 and 20 mg. Serial blood and urine samples were obtained up to 48 hours for pharmacokinetic analysis. Vardenafil and its metabolite were detected by high performance liquid chromatography tandem mass spectrometry assay.
Results
A total of 45 adverse events (AE) were reported in 22 subjects, including 5 AEs from placebo treatment, and all the AEs were mild, except one case of moderate nasal stuffiness. Vardenafil was absorbed after a single oral dose, with the tmax of 0.5-1.0 hours. The Cmax and AUClast were 10.21 ± 3.68 ug/L(mean ± SD) and 18.08 ± 7.44 ug×h/L in 5 mg dose group, 19.79 ± 12.13 ug/L and 38.61 ± 21.04 ug×h/L in 10 mg dose group and 53.16 ± 37.01 ug/L and 110.05 ± 69.65 ug×h/L in 20 mg dose group. Dose-linearity on AUClast and Cmax of vardenafil were observed in three dose groups. In all dose groups, the fraction excreted in urine was less than 1%.
Figures and Tables
Figure 2
Mean (arithmetic mean) - SD plasma concentration-time profiles of (a) vardenafil and (b) N-desethyl vardenafil in log scale after a single oral administration of vardenafil 5 mg, 10 mg and 20 mg. Error bars represent standard deviations.
Figure 3
Dose-normalized Cmax and AUClast after a single oral administration of vardenafil 5 mg, 10 mg and 20 mg. The box defines the upper quartile and lower quartile, and encloses 50% of the data. The median is depicted as a line with in the box. ((a): Dose-normalized Cmax, (b): dose-normalized AUClast).
Figure 4
Metabolic ratio between vardenafil and N-desethyl vardenafil after a single oral administration of vardenafil 5 mg, 10 mg and 20 mg. The box defines the upper quartile and lower quartile, and encloses 50% of the data. The median is depicted as a line with in the box.
Table 2
Pharmacokinetic parameters of vardenafil and N-desethyl vardenafil after oral administratioin of vardenafil
All data presented as arithmetic mean ± standard deviation except tmax. *Data presented as median (range). tmax: Time of maximum observed plasma concentration. Cmax: Maximum observed plasma concentration. AUClast: Areaunder the plasma concentration-time curve from zero time until the last measurable concentration. CL/F: Apparent clearance. t1/2: Termin alelimination half-life. Ae0-48h: Total Amount of unchanged drug excreted into the urine within time span 0 to 48h. fe/Fe: Fraction of the non-intravenously administered drug excreted into the urine. CLR: Renal clearance of the drug from plasma.
References
1. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004. 1(1):6–23.
2. Albersen M, Orabi H, Lue TF. Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. Gerontology. 2012. 58(1):3–14.
3. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010. 57(5):804–814.
4. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007. 120(2):151–157.
5. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005. 294(23):2996–3002.
6. Cho BL, Kim YS, Choi YS, Hong MH, Seo HG, Lee SY, Shin HC, Kim CH, Moon YS, Cha HS, Kim BS. Prevalence and risk factors for erectile dysfunction in primary care: results of a Korean study. Int J Impot Res. 2003. 15(5):323–328.
7. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994. 151(1):54–61.
8. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 2005. 45(9):987–1003.
9. Research CfDEa. NDA 021400 Levitra (Vardenafil Hydrochloride) Tablets: Clinical Pharmacology/Biopharmaceutics Review. 2003. Rockville, Md: Department of Health and Human Services, US Food and Drug Administration.
10. EMEA. Scientific discussion for the approval of Levitra [Online]. last visited on 27 May 2012.
11. Shon JH, Ku HY, Bae SY, Oh MK, Yeo CW, Bae SK, Shin JG. The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics. 2011. 21(12):820–828.
12. Dorne JL, Walton K, Renwick AG. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol. 2003. 41(2):201–224.
13. Park SY, Kang YS, Jeong MS, Yoon HK, Han KO. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther. 2008. 33(1):61–65.
14. Choi MK, Song IS. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. J Pharm Pharmacol. 2012. 64(8):1074–1083.
XML Download